Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $23 to $24.
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $23 to $24.